Tuesday, February 14, 2017 12:50:04 PM
_______________________________________
Bristol-Myers 'in play' - StreetInsider
Feb. 14, 2017 12:23 PM ET|By: Stephen Alpher, SA News Editor
Roche (OTCQX:RHHBY), Novartis (NYSE:NVS), and Pfizer (NYSE:PFE) are "thought to be kicking the tires," according to the report, which also cites Gilead (NASDAQ:GILD) as a potential buyer.
A deal could be worth as much as $72 per share.
BMY has popped 2% to $53.03.
__________________________________________
http://seekingalpha.com/news/3243260-bristol-myers-in-play-streetinsider
BMY
Recent BMY News
- Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 05/29/2024 10:59:00 AM
- Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms • Business Wire • 05/23/2024 09:05:00 PM
- OpenAI and News Corp Seal Partnership, DuPont de Nemours Announces Division, and More News • IH Market News • 05/23/2024 11:40:51 AM
- Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting • Business Wire • 05/23/2024 10:59:00 AM
- Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries • Business Wire • 05/22/2024 10:59:00 AM
- NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb • PR Newswire (US) • 05/22/2024 07:30:00 AM
- NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb • PR Newswire (US) • 05/22/2024 07:30:00 AM
- Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign • Business Wire • 05/21/2024 12:45:00 PM
- Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/21/2024 10:59:00 AM
- New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis • Business Wire • 05/16/2024 02:26:00 PM
- Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma • Business Wire • 05/16/2024 12:57:00 AM
- Arm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and More • IH Market News • 05/13/2024 11:16:03 AM
- Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial • Business Wire • 05/10/2024 08:30:00 PM
- Bristol Myers Squibb to Participate in Upcoming Investor Conferences • Business Wire • 05/07/2024 10:59:00 AM
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... • Business Wire • 05/06/2024 10:59:00 AM
- U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) • Business Wire • 05/06/2024 10:59:00 AM
- Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration • GlobeNewswire Inc. • 05/01/2024 12:00:00 PM
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • PR Newswire (US) • 04/29/2024 10:00:00 AM
- CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma • Business Wire • 04/26/2024 10:59:00 AM
- U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast • IH Market News • 04/25/2024 11:53:54 AM
- Bristol Myers Squibb Reports First Quarter Financial Results for 2024 • Business Wire • 04/25/2024 10:59:00 AM
- Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News • IH Market News • 04/23/2024 11:25:34 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster • Business Wire • 04/22/2024 10:59:00 AM
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) • Business Wire • 04/08/2024 03:30:00 PM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM